Miromatrix and their bioengineered pig-human hybrid organs 🐷The set up for a pump seems to be falling nicely into place, cheap, small cap, descent into oblivion, interesting tech, “undiscovered gem” feeling.
The volume is dastardly and it could still fall sub $2 before making a comeback.
They may pull a card out of their sleeve tomorrow at CareDx’s Xenotra
Key stats
Market capitalization
41.939MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.38USD
About Miromatrix Medical Inc
ISIN
US60471P1084
Sector
Health Technology
Industry
Biotechnology
Website
miromatrix.com
CEO
Jeff Ross
Headquarters
Eden Prairie
Employees
61
Founded
2009
Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. It offers perfusion decellularization and recellularization technology, as well as organ-derived biological products such as MIROMESH and MIRODERM for soft tissue reinforcement and advanced wound care. The company was founded in 2009 by Doris A. Taylor and Cohen Robert and is headquartered in Eden Prairie, MN.
MIRO Miromatrix Medical Price TargetMiromatrix Medical Inc. engages in the development of biological human organs to solve the chronic shortage of transplantable organs.
114,000 people in the U.S. are waiting for a life-saving organ transplant, and more than half will die due to a lack of available organs.
Miromatrix Medical trial i
See all ideas
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0